fig8

Figure 8. In vivo validation that LINC01133 promotes cisplatin resistance by inhibiting pyroptosis. (A) Tumor sizes in each group of BALB/c nude mice; (B) Excised tumor tissues from each group immediately after the experiment; (C) LINC01133 levels in tumor tissues measured by qRT-PCR; (D) Tumor growth curves plotted based on measured tumor volumes; (E) Comparison of final tumor weights of BALB/c nude mice across diverse groups; (F) IHC detection of Ki-67, E-cadherin, and N-cadherin expression in tumor tissues from diverse groups (20×). Scale bar: 50 μm; (G) TUNEL-positive cell death in tumor tissues detected by TUNEL staining (20×). Scale bar: 50 μm; (H) IHC detection of cleaved Caspase-1 and GSDMD-NT levels in tumor tissues from diverse groups (20×). Scale bar: 50 μm. Comparisons among multiple group means were performed with one-way ANOVA. ^*P < 0.05; ^**P < 0.01; ^***P < 0.001; ns: not significant. qRT-PCR: Quantitative reverse transcription-polymerase chain reaction; IHC: immunohistochemical; TUNEL: transferase dUTP nick-end labeling; ANOVA: analysis of variance; DDP: cisplatin; LPS: lipopolysaccharide; DSF: disulfiram.